The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 04, 2018

Filed:

Mar. 13, 2017
Applicant:

Cmpd Licensing, Llc, Conroe, TX (US);

Inventors:

Jay Richard Ray, II, Conroe, TX (US);

Charles D. Hodge, Conroe, TX (US);

Assignee:

CMPD Licensing, LLC, Conroe, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/56 (2006.01); A61K 31/67 (2006.01); A61K 31/195 (2006.01); A61K 31/4545 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61K 47/34 (2017.01); A61K 31/167 (2006.01);
U.S. Cl.
CPC ...
A61K 47/34 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/167 (2013.01); A61K 31/195 (2013.01); A61K 31/4545 (2013.01); A61K 31/56 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01);
Abstract

The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.


Find Patent Forward Citations

Loading…